An observational study in PTC, I-131 and Trop2, sponsored by Jiangxi Provincial Cancer Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Jiangxi Provincial Cancer Hospital · Observational
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (\^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected (approximately 30-50 cases each in the \^131I treatment-responsive group vs. the \^131I treatment-resistant group). Patients in the \^131I treatment-resistant group underwent \^18F-Trop2 PET-CT imaging.
Inclusion criteria:
Exclusion criteria:
Within the \^131I treatment-resistant group, comparisons were made between the rapidly progressing subgroup and the stable-disease subgroup under TSH-suppressive therapy in terms of clinicopathological features, tissue Trop2 expression levels, and SUVmax of metastatic lesions on \^18F-Trop2 PET-CT imaging. Factors influencing progression-free survival and overall survival in \^131I-resistant patients were analyzed.
Jiangxi Provincial Cancer Hospital is the lead sponsor of 33 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients who had undergone total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma and at least one radioactive iodine-131 (\^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected
Inclusion Criteria:( 1) History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC); (2) At least one course of \^131I internal radiotherapy. Exclusion Criteria:(1) Presence of other severe comorbidities; (2) Incomplete clinical or follow-up data.
The ¹³¹I treatment-responsive group was defined as patients who achieved successful radioactive iodine therapy (i.e., lesions disappeared or showed no long-term progression after radioiodine uptake).
Radiation: radioiodine-131 therapy
The ¹³¹I treatment-resistant group was defined as patients meeting any of the following criteria: No radioiodine uptake in metastatic tissues during the first ¹³¹I treatment, with insignificant decrease or an increase in serum Tg levels before and after therapy; Partial lesions exhibit radioiodine uptake while others showed no uptaking; Progressive metastatic disease despite evident radioiodine uptake.
Radiation: radioiodine-131 therapy
surgery, tsh inhibition therapy
Tumor size;
Lesion size was determined using CT imaging. Lymph nodes were assessed based on their shortest diameter, while other target lesions were evaluated based on their longest diameter. Each measurable lesion underwent an average measurement derived from a minimum of three readings, with all measurements conducted by the same individual to minimize measurement discrepancies. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were used to assess treatment response
Time frame: 6-60 months
Serological assessment
Including serum thyroglobulin (Tg) and serum anti-thyroglobulin antibody levels (TgAb) in thyrotropin-inhibited states, as well as tumor markers such as CEA
Time frame: 1-60months
Plan to share: Undecided — We will share our plan after our results be published
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangxi Provincial Cancer Hospital